| 04/07/21 |
Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS |
| 03/31/21 |
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing |
| 03/24/21 |
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test |
| 03/10/21 |
Natera and Genentech Initiate Phase III Trial Using Signatera™ as a Companion Diagnostic for Atezolizumab in Early-Stage Muscle-Invasive Bladder Cancer |
| 02/25/21 |
Natera Reports Fourth Quarter and Year 2020 Financial Results |
| 02/23/21 |
Natera to Participate in the Cowen 41st Annual Health Care Conference |
| 02/18/21 |
Natera Announces Fourth Quarter and Fiscal 2020 Earnings Conference Call |
| 02/17/21 |
Natera and Personalis Partner for Personalized Monitoring in Oncology |
| 02/11/21 |
Natera to Participate in Upcoming Investor Conferences |
| 02/03/21 |
Panorama® SMART Study Confirms Market-Leading Performance in Largest Prospective NIPT Trial to Date |
| 02/01/21 |
SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected |
| 01/20/21 |
Natera Files Patent Infringement Suit Against Inivata |
| 01/14/21 |
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing |
| 01/12/21 |
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium |
| 01/05/21 |
Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare Conference |
